Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Chronic peripheral ghrelin injection exerts antifibrotic effects by increasing growth differentiation factor 15 in rat hearts with myocardial fibrosis induced by isoproterenol

Q. Ren, P. Lin, Q. Wang, B. Zhang, L. Feng

. 2020 ; 69 (3) : 439-450. [pub] 20191219

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21015658

This study aimed to investigate the anti-fibrotic effects of ghrelin in isoproterenol (ISO)-induced myocardial fibrosis and the underlying mechanism. Sprague-Dawley rats were randomized to control, ISO, and ISO + ghrelin groups. ISO (2 mg/kg per day, subcutaneous) or vehicle was administered once daily for 7 days, then ghrelin (100 microg/kg per day, subcutaneous) was administered once daily for the next 3 weeks. Ghrelin treatment greatly improved the cardiac function of ISO-treated rats. Ghrelin also decreased plasma brain natriuretic peptide level and ratios of heart weight to body weight and left ventricular weight to body weight. Ghrelin significantly reduced myocardial collagen area and hydroxyproline content, accompanied by decreased mRNA levels of collagen type I and III. Furthermore, ghrelin increased plasma level of growth differentiation factor 15 (GDF15) and GDF15 mRNA and protein levels in heart tissues, which were significantly decreased with ISO alone. The phosphorylation of Akt at Ser473 and GSK-3beta at Ser9 was decreased with ISO, and ghrelin significantly reversed the downregulation of p-Akt and p-GSK-3beta. Mediated by GDF15, ghrelin could attenuate ISO-induced myocardial fibrosis via Akt-GSK-3beta signaling.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc21015658
003      
CZ-PrNML
005      
20210618141657.0
007      
ta
008      
210604s2020 xr ad f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934183 $2 doi
035    __
$a (PubMed)31852204
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Ren, Q. $u Geriatric Department of the Third Hospital of Hangzhou, Hangzhou, China
245    10
$a Chronic peripheral ghrelin injection exerts antifibrotic effects by increasing growth differentiation factor 15 in rat hearts with myocardial fibrosis induced by isoproterenol / $c Q. Ren, P. Lin, Q. Wang, B. Zhang, L. Feng
504    __
$a Literatura
520    9_
$a This study aimed to investigate the anti-fibrotic effects of ghrelin in isoproterenol (ISO)-induced myocardial fibrosis and the underlying mechanism. Sprague-Dawley rats were randomized to control, ISO, and ISO + ghrelin groups. ISO (2 mg/kg per day, subcutaneous) or vehicle was administered once daily for 7 days, then ghrelin (100 microg/kg per day, subcutaneous) was administered once daily for the next 3 weeks. Ghrelin treatment greatly improved the cardiac function of ISO-treated rats. Ghrelin also decreased plasma brain natriuretic peptide level and ratios of heart weight to body weight and left ventricular weight to body weight. Ghrelin significantly reduced myocardial collagen area and hydroxyproline content, accompanied by decreased mRNA levels of collagen type I and III. Furthermore, ghrelin increased plasma level of growth differentiation factor 15 (GDF15) and GDF15 mRNA and protein levels in heart tissues, which were significantly decreased with ISO alone. The phosphorylation of Akt at Ser473 and GSK-3beta at Ser9 was decreased with ISO, and ghrelin significantly reversed the downregulation of p-Akt and p-GSK-3beta. Mediated by GDF15, ghrelin could attenuate ISO-induced myocardial fibrosis via Akt-GSK-3beta signaling.
650    _2
$a agonisté adrenergních beta-receptorů $x farmakologie $7 D000318
650    _2
$a zvířata $7 D000818
650    _2
$a kardiomyopatie $x chemicky indukované $x farmakoterapie $x metabolismus $x patologie $7 D009202
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a fibróza $x chemicky indukované $x farmakoterapie $x patologie $7 D005355
650    _2
$a ghrelin $x aplikace a dávkování $7 D054439
650    _2
$a růstový diferenciační faktor 15 $x metabolismus $7 D055436
650    _2
$a srdce $x účinky léků $x patofyziologie $7 D006321
650    _2
$a isoprenalin $x farmakologie $7 D007545
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myokard $x metabolismus $x patologie $7 D009206
650    _2
$a protoonkogenní proteiny c-akt $x metabolismus $7 D051057
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lin, P. $u Geriatric Department of the Third Hospital of Hangzhou, Hangzhou, China
700    1_
$a Wang, Q. $u Geriatric Department of the Third Hospital of Hangzhou, Hangzhou, China
700    1_
$a Zhang, B. $u Geriatric Department of the Third Hospital of Hangzhou, Hangzhou, China
700    1_
$a Feng, L. $u Geriatric Department of the Third Hospital of Hangzhou, Hangzhou, China
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 69, č. 3 (2020), s. 439-450
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31852204 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20210604 $b ABA008
991    __
$a 20210611163520 $b ABA008
999    __
$a ok $b bmc $g 1664039 $s 1136066
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 69 $c 3 $d 439-450 $e 20191219 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK118 $a Pubmed-20210604

Find record

Citation metrics

Archiving options